Company profile
FIECON | Leaders in Health Economics
FIECON combine the forces of commercial strategy and technical rigour to provide impactful solutions, which shape the launch of your product around the world. This is underpinned with experience in over 40 countries across a variety of disease areas.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNjk5OTI1OGFkaXF6a2N4
Published 24 Sep 2024 11:44
CS01 | Transaction MzQzMzIzNzUxMmFkaXF6a2N4
Published 23 Aug 2024 11:05
Company registered at Companies House
1 May 2017 to 30 Apr 2020
Diabetic Foot Ulcers (DFUs) are a major worldwide issue, occurring in 15% of diabetes sufferers and 56% of these patients die within 5 years of the first occurrence. The recurrence rate is approximately 50% per annum with current methods and treatment requiring a multidisciplinary assessment (including diabetes specialists, surgeons and podiatrists). Ther...
